Yu Jingbin, Zhang Lei, Zhang Hui
Department of Cardiology, Zibo Central Hospital, Zibo, Shandong 255000, P.R. China.
Exp Ther Med. 2020 Mar;19(3):2053-2058. doi: 10.3892/etm.2020.8438. Epub 2020 Jan 27.
Effect of atorvastatin combined with routine therapy on the expression of hypoxia inducible factor (HIF-1) and vascular endothelial growth factor (VEGF) in rats with acute myocardial infarction (AMI) and its therapeutic effect were investigated. The rat models of acute myocardial infarction were established and divided into routine therapy, study, model, single drug and control group according to the treatment plan, with 10 cases in each group. Enzyme-linked immunosorbent assay (ELISA) was used to detect the concentration of HIF-1 and VEGF in serum of rats before treatment (T0), and 3 days (T1), 5 days (T2) and 7 days (T3) after treatment, and the cardiac function was measured at the same time. The concentrations of HIF-1 and VEGF in serum of the study group and the routine therapy group after treatment were significantly higher than those before treatment. The concentrations of HIF-1 and VEGF in serum of model group at T0 were significantly lower than those at T3 (P<0.05). After treatment, the concentrations of HIF-1 and VEGF in serum of the study group were significantly higher than those of the routine therapy, the model and the control group (P<0.05). One week after administration, there were significant differences in the left ventricular function among the five groups (P<0.001). The left ventricular function in the study group was better than that in the routine therapy, model and control group. The levels of HIF-1 and VEGF in the serum of rats with myocardial infarction were negatively correlated with LVIDs and LVIDd, and positively correlated with LVEF% and LVFS%. In conclusion, atorvastatin combined with routine therapy can better reduce serum HIF-1 and VEGF levels and improve the left ventricular function in rats than routine therapy.
研究阿托伐他汀联合常规治疗对急性心肌梗死（AMI）大鼠缺氧诱导因子（HIF-1）和血管内皮生长因子（VEGF）表达的影响及其治疗效果。建立大鼠急性心肌梗死模型，并根据治疗方案分为常规治疗组、研究组、模型组、单药组和对照组，每组10只。采用酶联免疫吸附测定（ELISA）法检测大鼠治疗前（T0）及治疗后3天（T1）、5天（T2）和7天（T3）血清中HIF-1和VEGF的浓度，并同时测量心功能。治疗后研究组和常规治疗组血清中HIF-1和VEGF的浓度明显高于治疗前。模型组T0时血清中HIF-1和VEGF的浓度明显低于T3时（P<0.05）。治疗后，研究组血清中HIF-1和VEGF的浓度明显高于常规治疗组、模型组和对照组（P<0.05）。给药1周后，五组左心室功能有显著差异（P<0.001）。研究组左心室功能优于常规治疗组、模型组和对照组。心肌梗死大鼠血清中HIF-1和VEGF水平与左心室舒张末期内径（LVIDs）和左心室舒张末期内径（LVIDd）呈负相关，与左心室射血分数（LVEF%）和左心室短轴缩短率（LVFS%）呈正相关。综上所述，阿托伐他汀联合常规治疗比常规治疗能更好地降低大鼠血清HIF-1和VEGF水平，改善左心室功能。
